Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B..

Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22.

2.

Future directions in the treatment of androgen-independent prostate cancer.

Petrylak DP.

Urology. 2005 Jun;65(6 Suppl):8-12. Review.

PMID:
15939077
3.

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.

Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, Yu Y, Yang C, Wang C, Xu T, Xu Z, Zou Q.

Medicine (Baltimore). 2016 Sep;95(39):e4801. doi: 10.1097/MD.0000000000004801. Review.

4.

Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.

Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H.

Urology. 2002 Dec;60(6):1111. Review.

PMID:
12475686

Supplemental Content

Support Center